2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1774

Sepsis Is The Leading Cause Of Hospital Mortality In Dermatomyositis/Polymyositis: Data From a Population-Based Study
Abstract Number: 2337

Serious Adverse Events Associated With Using Biological Agents To Treat Rheumatic Diseases: Network Meta-Analysis From a National Guideline Panel
Abstract Number: 1672

Serious Cardiovascular Events Risk Factors In Giant Cell Arteritis. A Population-Based Study In The French Apogee Cohort
Abstract Number: 780

Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants
Abstract Number: 423

Serological Biomarkers For The Development Of Rheumatoid Arthritis Related Interstitial Lung Disease
Abstract Number: 879

Serological Biomarkers Of Specific Mode Of Action For Early Identification Of Rheumatoid Arthritis Patients Who Respond To Anti-IL6 Or Anti-TNF Treatment
Abstract Number: 1250

Serological Markers Of Structural Integrity and Inflammation Is Associated With Pain In Osteoarthritis
Abstract Number: 1583

Serositis In Systemic Lupus Erythematosus: Prevalence, Recurrence, Treatment and Outcome
Abstract Number: L13

Serum 14-3-3η Marks RA Development in Arthralgia and Radiographic Progression in Early RA Patients
Abstract Number: 1389

Serum 14-3-3η Precedes and Independently Predicts The Development Of RA
Abstract Number: 1790

Serum Amyloid A Levels Model Rheumatoid Arthritis Disease Activity Better Than C-Reactive Protein Levels Especially During Treatment With Anti-Tumor Necrosis Factor α Therapy (Etanercept)
Abstract Number: 622

Serum Anti-Apolipoprotein 1 Antibodies Are Present In a Quarter Of Patients With Systemic Lupus Erythematosus At The Time Of Diagnosis and Are Associated With Earlier Mortality
Abstract Number: 2615

Serum Beta 2 Microglobulin and Its Association With Disease Activity in Patients With Behcet’s Disease
Abstract Number: 642

Serum Concentrations Of Type I Interferon-Regulated Chemokines Are Associated With Disease Activity In Systemic Lupus Erythematosus
Abstract Number: 349

Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].